EvidenceAlerts

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10. (Evidence-based guideline)
Abstract
N/A

Related DynaMed Plus Topics

Ratings
Discipline Area Score
Family Medicine (FM)/General Practice (GP) 7 / 7
General Internal Medicine-Primary Care(US) 7 / 7
Internal Medicine 6 / 7
Endocrine 6 / 7
Cardiology 5 / 7
Comments from MORE raters

Cardiology rater

An important evidence-based update on the management of hypercholesterolemia!

Cardiology rater

Very detailed analysis and suggestions with more summary take-home messages that should be useful.

Endocrine rater

A useful and practical guide concentrating appropriately on the use of statins and their side effects. The CV risk threshold for statin introduction remains 7.5%. Quite a lot of the suggestions made are labelled as 'reasonable' - presumably meaning that the evidence is inconclusive. PCSK9 inhibitors (not available in my country) are still too expensive to win a recommendation. The evidence supporting greater use of coronary calcium studies is not clear.

General Internal Medicine-Primary Care(US) rater

This is the full set of guidelines for treating cholesterol that was published in August 2018 and is > 60 pages long. Pros: It is organized by patient risk category, it has all the evidence in one place, and it`s endorsed by just about every group out here. Cons: it is quite long and it may take a minute to locate the answer you want. Still, probably everyone should have this article bookmarked.

General Internal Medicine-Primary Care(US) rater

There was a synopsis of this in the Annals of Internal Medicine last month.

Internal Medicine rater

Guidelines are usually highly clinically relevant. This guideline is no exception given the broad-reaching topic and highly reputable sponsoring societies.
Comments from EvidenceAlerts subscribers

No subscriber has commented on this article yet.